Cargando…

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting

Objective biomarkers for Parkinson’s Disease (PD) could aid early and specific diagnosis, effective monitoring of disease progression, and improved design and interpretation of clinical trials. Although alpha-synuclein remains a biomarker candidate of interest, the multifactorial and heterogenous na...

Descripción completa

Detalles Bibliográficos
Autores principales:	Youssef, Priscilla, Hughes, Laura, Kim, Woojin S., Halliday, Glenda M., Lewis, Simon J. G., Cooper, Antony, Dzamko, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10063670/ https://www.ncbi.nlm.nih.gov/pubmed/36997567 http://dx.doi.org/10.1038/s41598-023-32480-0

Ejemplares similares

Plasma UCHL1, GFAP, Tau, and NfL Are Not Different in Young Healthy Persons With Mild COVID-19 Symptoms Early in the Pandemic: A Pilot Study
por: Rogatzki, Matthew J., et al.
Publicado: (2023)

Comparison of Different Platform Immunoassays for the Measurement of Plasma Alpha-Synuclein in Parkinson’s Disease Patients
por: Youssef, Priscilla, et al.
Publicado: (2021)

Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury
por: Sass, Dilorom, et al.
Publicado: (2021)

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias
por: Baiardi, Simone, et al.
Publicado: (2022)

Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Minocycline treatment in clinically isolated syndrome and serum NfL, GFAP, and metalloproteinase levels
por: Camara-Lemarroy, Carlos, et al.
Publicado: (2022)

Emergence delirium and postoperative delirium associated with high plasma NfL and GFAP: an observational study
por: Liu, Xingyang, et al.
Publicado: (2023)

Parkinson’s disease-implicated kinases in the brain; insights into disease pathogenesis
por: Dzamko, Nicolas, et al.
Publicado: (2014)

Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis
por: Barro, Christian, et al.
Publicado: (2022)

Parkinson’s progression prediction using machine learning and serum cytokines
por: Ahmadi Rastegar, Diba, et al.
Publicado: (2019)

Neurochemical Monitoring of Traumatic Brain Injury by the Combined Analysis of Plasma Beta-Synuclein, NfL, and GFAP in Polytraumatized Patients
por: Halbgebauer, Rebecca, et al.
Publicado: (2022)

Quantification and prospective evaluation of serum NfL and GFAP as blood-derived biomarkers of outcome in acute ischemic stroke patients
por: Ferrari, Federica, et al.
Publicado: (2023)

Live cell in situ lysosomal GCase activity correlates to alpha-synuclein levels in human differentiated neurons with LRRK2 and GBA1 mutations
por: Labrador-Garrido, Adahir, et al.
Publicado: (2023)

Effect of Estimated Blood Volume and Body Mass Index on GFAP and NfL Levels in the Serum and CSF of Patients With Multiple Sclerosis
por: Yalachkov, Yavor, et al.
Publicado: (2022)

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients
por: Gust, Juliane, et al.
Publicado: (2022)

Reduced glucocerebrosidase activity in monocytes from patients with Parkinson’s disease
por: Atashrazm, Farzaneh, et al.
Publicado: (2018)

Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson’s Disease Patient Monocytes and Inversely Correlates with Motor Severity
por: Hughes, Laura P., et al.
Publicado: (2021)

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
por: Schindler, Patrick, et al.
Publicado: (2021)

Central nervous system biomarkers GFAp and NfL associate with post-acute cognitive impairment and fatigue following critical COVID-19
por: Bark, Lovisa, et al.
Publicado: (2023)

The Use of Biologics in NFL Athletes: An Expert Consensus of NFL Team Physicians
por: Murray, Iain R., et al.
Publicado: (2023)

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Role of the Long Non-Coding RNA MAPT-AS1 in Regulation of Microtubule Associated Protein Tau (MAPT) Expression in Parkinson's Disease
por: Coupland, Kirsten G., et al.
Publicado: (2016)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

A small molecule toll-like receptor antagonist rescues α-synuclein fibril pathology
por: Chedid, Jessica, et al.
Publicado: (2022)

Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition
por: Rauchmann, Boris Stephan, et al.
Publicado: (2021)

UCHL1 regulates oxidative activity in skeletal muscle
por: Gao, Hongbo, et al.
Publicado: (2020)

Effect of Posterior Glenoid Labral Tears at the NFL Combine on Future NFL Performance
por: Murphy, Colin P., et al.
Publicado: (2018)

Epidemiology of Navicular Injury at the NFL Combine and Their Impact on an Athlete’s Prospective NFL Career
por: Vopat, Bryan, et al.
Publicado: (2017)

Can NFL Combine Results be Used to Estimate NFL Defensive Players Longevity?
por: Pollock, Jordan Riley, et al.
Publicado: (2021)

A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort
por: van Dam, Maureen, et al.
Publicado: (2023)

Loss of UCHL1 rescues the defects related to Parkinson’s disease by suppressing glycolysis
por: Ham, Su Jin, et al.
Publicado: (2021)

Expression analysis of the long non-coding RNA antisense to Uchl1 (AS Uchl1) during dopaminergic cells' differentiation in vitro and in neurochemical models of Parkinson's disease
por: Carrieri, Claudia, et al.
Publicado: (2015)

Truth, Justice, and the NFL Way: Review: League of Denial: The NFL, Concussions, and the Battle for Truth
por: Stieg, Philip E.
Publicado: (2014)

Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology
por: Dzamko, Nicolas, et al.
Publicado: (2016)

Injuries and home advantage in the NFL
por: Jones, Marshall B.
Publicado: (2016)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

UCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan
por: Miyake, Yoshihiro, et al.
Publicado: (2012)

UCHL1 Regulates Lipid and Perilipin 2 Level in Skeletal Muscle
por: Antony, Ryan, et al.
Publicado: (2022)

Single‐Molecule Counting Coupled to Rapid Amplification Enables Detection of α‐Synuclein Aggregates in Cerebrospinal Fluid of Parkinson's Disease Patients
por: Bhumkar, Akshay, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpqdg6ntn0umegku98q34ur8k7